These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 12811515

  • 1. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS, Kemp TJ.
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [Abstract] [Full Text] [Related]

  • 2. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
    Déjosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD.
    Cell Death Differ; 2000 Nov 15; 7(11):1127-36. PubMed ID: 11139287
    [Abstract] [Full Text] [Related]

  • 4. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.
    Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 6. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F.
    Biochem Pharmacol; 2006 Mar 14; 71(6):791-8. PubMed ID: 16438941
    [Abstract] [Full Text] [Related]

  • 7. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB.
    Clin Cancer Res; 2003 Oct 01; 9(12):4537-45. PubMed ID: 14555528
    [Abstract] [Full Text] [Related]

  • 8. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.
    Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK.
    Int J Oncol; 2004 May 01; 24(5):1133-40. PubMed ID: 15067334
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A, McDonnell TJ, Meyn RE.
    Cancer Chemother Pharmacol; 2002 Jul 15; 50(1):46-52. PubMed ID: 12111111
    [Abstract] [Full Text] [Related]

  • 11. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S, Singh TR, Srivastava RK.
    Prostate; 2004 Sep 15; 61(1):35-49. PubMed ID: 15287092
    [Abstract] [Full Text] [Related]

  • 12. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Int J Mol Med; 2006 Jul 15; 18(1):41-7. PubMed ID: 16786154
    [Abstract] [Full Text] [Related]

  • 13. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 14. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C, King DL, Norris JS.
    Cancer Gene Ther; 2002 Feb 15; 9(2):164-72. PubMed ID: 11857034
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.